AB Corporate Bond ETF (NASDAQ:EYEG) Stock Passes Below 200-Day Moving Average – Should You Sell?

Posted by James Quigley on Jul 30th, 2026

AB Corporate Bond ETF (NASDAQ:EYEG – Get Free Report) crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $35.38 and traded as low as $34.58. AB Corporate Bond ETF shares last traded at $34.58, with a volume of 415 shares trading hands.

AB Corporate Bond ETF Trading Down 0.4%

The firm has a market capitalization of $27.66 million, a P/E ratio of -20.58 and a beta of 0.17. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.01. The firm has a 50 day moving average of $35.10 and a 200-day moving average of $35.38.

AB Corporate Bond ETF Cuts Dividend

The business also recently disclosed a monthly dividend, which was paid on Tuesday, July 7th. Shareholders of record on Wednesday, July 1st were issued a $0.1358 dividend. The ex-dividend date of this dividend was Wednesday, July 1st. This represents a c) annualized dividend and a yield of 4.7%. AB Corporate Bond ETF’s payout ratio is currently -102.98%.

Institutional Trading of AB Corporate Bond ETF

A hedge fund recently bought a new position in AB Corporate Bond ETF stock. Jane Street Group LLC purchased a new position in AB Corporate Bond ETF (NASDAQ:EYEG – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,496 shares of the specialty pharmaceutical company’s stock, valued at approximately $232,000. Jane Street Group LLC owned 0.87% of AB Corporate Bond ETF as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 64.16% of the company’s stock.

AB Corporate Bond ETF Company Profile

(Get Free Report)

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.